Administrative Core
行政核心
基本信息
- 批准号:10667436
- 负责人:
- 金额:$ 39.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccountabilityAddressAdministrative PersonnelAdvisory CommitteesAgingAlzheimer&aposs DiseaseApolipoprotein EBiochemicalBioinformaticsBiological ModelsBiologyBiometryClinicCollaborationsCommunitiesComplexDataData SetDedicationsDepartment chairEnsureEventGenotypeGoalsImpaired cognitionIndividualInstitutionInterdisciplinary StudyKnowledgeKnowledge PortalLDL-Receptor Related Protein 1LeadLeadershipNeurologyNeurosciencesPathogenesisPathogenicityPathway interactionsPositioning AttributeProgress ReportsPropertyProtein IsoformsPublicationsQuality ControlReagentRecording of previous eventsReproducibilityResearchResearch PersonnelResource SharingResourcesRiskRoleSiteStructureSystemTherapeuticUnited States National Institutes of HealthUniversitiesWashingtonanalytical methoddata accessdata managementdata sharingdesignexperienceinnovationmedical schoolsmeetingsnervous system disordernovelprogramsprotective effectresearch in practiceresponsible research conductsharing platformsymposiumsynergismweb portalweb site
项目摘要
PROJECT SUMMARY (APOE U19 Core A: Administrative Core)
The Administrative Core will lead this U19 project by providing administrative, fiscal, and scientific oversight
and promoting synergy of all Cores and Projects to address the ApoE Cascade Hypothesis. Core A will serve
several functions to facilitate the scientific objectives and rigor of this U19. It will also serve the broader
scientific community by sharing knowledge, resources, and datasets through a web portal and by promoting
collaboration through an annual ApoE Symposium. Core A will cooperate fully with NIA initiatives with a
dedicated leadership team and administrative personnel with relevant experience. As the Co-PIs of this U19
project and Co-Leaders of Core A, Drs. Guojun Bu (Mayo Clinic Jacksonville) and David Holtzman
(Washington University in St. Louis) are recognized leaders in the apoE field; each has more than 25 years of
experience studying apoE and apoE receptors as they relate to the pathogenesis of AD and other aging-
related conditions. Drs. Bu and Holtzman have a long history of collaboration and are well positioned to share
leadership roles for this U19 program at the two coordinating institutions. They also have strong leadership
experience each serving as a Department Chair and an Associate Director of Alzheimer’s Disease Research
Center at their respective institution. Together with Dr. Alison Goate, who will serve as the Site-PI at Icahn
School of Medicine at Mount Sinai, they will ensure integration and synergy across the U19 by pursuing the
following aims: Aim 1: Provide administrative structure, fiscal oversight, and site coordination for the U19
program. Aim 2: Assume responsibility for the quality control of the U19 activities by ensuring responsible
conduct of research, rigor, and reproducibility of research practices, and by ensuring compliance with all
internal and external regulatory requirements. Promote and track open-access publications and facilitate
submission of progress reports to NIH. Aim 3: Promote the scientific direction and integration of the U19
components by organizing meetings of the Internal Steering Committee and External Advisory Committee. Aim
4: Develop and maintain an apoE website what will serve as knowledge portal, and resource and data sharing
platform. Aim 5: Organize Annual ApoE Symposium for U19 investigators as well as the broader scientific
community to interact and share research findings. These innovative aims will ensure that the robust and
rigorous efforts by the U19 team investigators will lead to new discoveries to inform therapeutic strategies.
项目概要(APOE U19核心A:行政核心)
行政核心将通过提供行政、财政和科学监督来领导这个U19项目。
促进所有核心和项目的协同作用,以解决ApoE级联假说。核心A将服务于
几个功能,以促进科学的目标和严谨性,这U19。它还将服务于更广泛的
科学界通过门户网站共享知识、资源和数据集,
通过年度ApoE研讨会进行合作。核心A将与NIA倡议充分合作,
具有相关经验的专职领导团队和行政人员。作为U19的联合PI
项目和核心A的共同负责人,马约诊所杰克逊维尔的卜国军博士和大卫霍尔茨曼博士
(圣路易斯华盛顿大学)是apoE领域公认的领导者;每个人都有超过25年的
有研究apoE和apoE受体的经验,因为它们与AD和其他衰老的发病机制有关-
相关条件。Bu博士和Holtzman博士有着悠久的合作历史,并有能力分享
在这两个协调机构的U19计划的领导作用。他们也有强有力的领导
分别担任系主任和阿尔茨海默病研究副主任
在各自的机构。Alison Goate博士将担任Icahn的研究中心PI
医学院在西奈山,他们将确保整个U19的整合和协同作用,通过追求
目标1:为U19提供行政结构、财政监督和现场协调
程序.目标2:负责U19活动的质量控制,确保
进行研究,严谨性和研究实践的可重复性,并确保遵守所有
内部和外部监管要求。促进和跟踪开放获取出版物,
向NIH提交进度报告。目标3:促进U19的科学方向和一体化
通过组织内部指导委员会和外部咨询委员会的会议,加强了各组成部分的工作。目的
4:开发和维护apoE网站,作为知识门户,共享资源和数据
平台目标5:为U19研究者以及更广泛的科学家组织年度ApoE研讨会
社区互动和分享研究成果。这些创新目标将确保
U19团队研究人员的严格努力将导致新的发现,为治疗策略提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Takahisa Kanekiyo其他文献
Takahisa Kanekiyo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Takahisa Kanekiyo', 18)}}的其他基金
Neuronal ABCA7 loss of function and Alzheimer’s disease
神经元 ABCA7 功能丧失与阿尔茨海默病
- 批准号:
10629715 - 财政年份:2023
- 资助金额:
$ 39.18万 - 项目类别:
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain
通过将 VGF 输送至大脑来治疗阿尔茨海默病的治疗策略
- 批准号:
10738951 - 财政年份:2023
- 资助金额:
$ 39.18万 - 项目类别:
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease
增强 APOE2 在大脑中的表达,用于阿尔茨海默病的治疗策略
- 批准号:
10208342 - 财政年份:2021
- 资助金额:
$ 39.18万 - 项目类别:
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's Disease
增强 APOE2 在大脑中的表达,用于阿尔茨海默病的治疗策略
- 批准号:
10514954 - 财政年份:2021
- 资助金额:
$ 39.18万 - 项目类别:
Pathogenic mechanisms of ABCA7 in Alzheimer's disease
ABCA7在阿尔茨海默病中的发病机制
- 批准号:
9221000 - 财政年份:2017
- 资助金额:
$ 39.18万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39.18万 - 项目类别:
Research Grant